Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-51151
Mar Drugs 2022 Nov 14;2011:. doi: 10.3390/md20110715.
Show Gene links Show Anatomy links

Implication of Echinochrome A in the Plasticity and Damage of Intestinal Epithelium.

Ahn JS , Shin YY , Oh SJ , Song MH , Kang MJ , Park SY , Nguyen PT , Nguyen DK , Kim HK , Han J , Vasileva EA , Mishchenko NP , Fedoreyev SA , Stonik VA , Seo Y , Lee BC , Kim HS .


???displayArticle.abstract???
The diverse therapeutic feasibility of the sea urchin-derived naphthoquinone pigment, Echinochrome A (Ech A), has been studied. Simple and noninvasive administration routes should be explored, to obtain the feasibility. Although the therapeutic potential has been proven through several preclinical studies, the biosafety of orally administered Ech A and its direct influence on intestinal cells have not been evaluated. To estimate the bioavailability of Ech A as an oral administration drug, small intestinal and colonic epithelial organoids were developed from mice and humans. The morphology and cellular composition of intestinal organoids were evaluated after Ech A treatment. Ech A treatment significantly increased the expression of LGR5 (~2.38-fold change, p = 0.009) and MUC2 (~1.85-fold change, p = 0.08). Notably, in the presence of oxidative stress, Ech A attenuated oxidative stress up to 1.8-fold (p = 0.04), with a restored gene expression of LGR5 (~4.11-fold change, p = 0.0004), as well as an increased expression of Ly6a (~3.51-fold change, p = 0.005) and CLU (~2.5-fold change, p = 0.01), markers of revival stem cells. In conclusion, Ech A is harmless to intestinal tissues; rather, it promotes the maintenance and regeneration of the intestinal epithelium, suggesting possible beneficial effects on the intestine when used as an oral medication.

???displayArticle.pubmedLink??? 36421992
???displayArticle.link??? Mar Drugs
???displayArticle.grants??? [+]


References [+] :
Artegiani, Use and application of 3D-organoid technology. 2018, Pubmed